CC-486 and Venetoclax for Acute Myeloid Leukemia - Trial NCT05287568
Access comprehensive clinical trial information for NCT05287568 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Colorado, Denver and is currently Recruiting. The study focuses on AML. Target enrollment is 22 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Colorado, Denver
Timeline & Enrollment
Phase 1
Mar 15, 2022
Mar 01, 2029
Primary Outcome
Determine the maximum tolerated dose of CC-486 in combination with venetoclax
Summary
This is an open label, dose escalation Phase I single institution pilot study for relapsed
 and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the
 completion of dose escalation and after establishment of the MTD or recommended dose of
 CC-486 with venetoclax, an expansion phase will commence, using venetoclax with the MTD of
 CC-486 in relapsed/refractory patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05287568
Non-Device Trial